
Pavan Muttil

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1262432/publications.pdf Version: 2024-02-01



Ρανλαί Μιιττιί

#	Article	IF	CITATIONS
1	Inhalable particles containing isoniazid and rifabutin as adjunct therapy for safe, efficacious and relapse-free cure of experimental animal tuberculosis in one month. Tuberculosis, 2021, 128, 102081.	0.8	8
2	Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51. Viruses, 2021, 13, 1113.	1.5	6
3	Design and Optimization of a Temperature-Stable Dry Powder BCG Vaccine. Pharmaceutical Research, 2020, 37, 11.	1.7	22
4	Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2020, 63, 10984-11011.	2.9	30
5	Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing. KONA Powder and Particle Journal, 2019, 36, 129-144.	0.9	27
6	Toxic Effects of Particulate Matter Derived from Dust Samples Near the Dzhidinski Ore Processing Mill, Eastern Siberia, Russia. Cardiovascular Toxicology, 2019, 19, 401-411.	1.1	9
7	Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9. Human Vaccines and Immunotherapeutics, 2019, 15, 1995-2002.	1.4	20
8	Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer. Antiviral Research, 2019, 166, 56-65.	1.9	38
9	Targeted Delivery of Antibiotics Using Microparticles to Combat Multidrug-Resistant Tuberculosis. , 2019, , 441-457.		0
10	Respirable Uranyl-Vanadate-Containing Particulate Matter Derived From a Legacy Uranium Mine Site Exhibits Potentiated Cardiopulmonary Toxicity. Toxicological Sciences, 2018, 164, 101-114.	1.4	35
11	Respiratory Tract Deposition and Distribution Pattern of Microparticles in Mice Using Different Pulmonary Delivery Techniques. Vaccines, 2018, 6, 41.	2.1	15
12	Delivery of Therapeutics to the Lung. Methods in Molecular Biology, 2018, 1809, 415-429.	0.4	2
13	Pulmonary Delivery of Magnetically Targeted Nano-in-Microparticles. Methods in Molecular Biology, 2017, 1530, 369-378.	0.4	3
14	Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 116-120.	4.5	23
15	A novel approach to study the pMDI plume using an infrared camera and to evaluate the aerodynamic properties after varying the time between actuations. International Journal of Pharmaceutics, 2017, 526, 41-49.	2.6	6
16	<i>In Vivo</i> Pulmonary Delivery and Magnetic-Targeting of Dry Powder Nano-in-Microparticles. Molecular Pharmaceutics, 2017, 14, 4741-4750.	2.3	48
17	Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs. Journal of Pharmaceutical Sciences, 2017, 106, 331-337.	1.6	21
18	Preparation and Characterization of Magnetic Nano-in-Microparticles for Pulmonary Delivery. Methods in Molecular Biology, 2017, 1530, 99-108.	0.4	4

Pavan Muttil

#	Article	IF	CITATIONS
19	Longitudinal Assessment of Lung Cancer Progression in Mice Using the Sodium lodide Symporter Reporter Gene and SPECT/CT Imaging. PLoS ONE, 2016, 11, e0169107.	1.1	7
20	Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus. Molecular Pharmaceutics, 2016, 13, 1646-1655.	2.3	48
21	A stable live bacterial vaccine. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 103, 109-117.	2.0	21
22	Oral Tolerance to Environmental Mycobacteria Interferes with Intradermal, but Not Pulmonary, Immunization against Tuberculosis. PLoS Pathogens, 2016, 12, e1005614.	2.1	29
23	Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. Vaccine, 2015, 33, 3346-3353.	1.7	54
24	Spray-Dried Multiscale Nano-biocomposites Containing Living Cells. ACS Nano, 2015, 9, 6961-6977.	7.3	24
25	Preparation and Characterization of Novel Magnetic Nano-in-Microparticles for Site-Specific Pulmonary Drug Delivery. Molecular Pharmaceutics, 2013, 10, 3574-3581.	2.3	42
26	Pharmacokinetics of Sequential Doses of Capreomycin Powder for Inhalation in Guinea Pigs. Antimicrobial Agents and Chemotherapy, 2012, 56, 2612-2618.	1.4	38
27	Isoxyl assays in plasma. Journal of Pharmaceutical and Biomedical Analysis, 2012, 60, 1-6.	1.4	5
28	Pulmonary immunization for TB with live cell-based vaccines: the importance of the delivery route. Therapeutic Delivery, 2011, 2, 1519-1522.	1.2	1
29	Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice. Tuberculosis, 2011, 91, 107-110.	0.8	16
30	Immunization of Guinea Pigs with Novel Hepatitis B Antigen as Nanoparticle Aggregate Powders Administered by the Pulmonary Route. AAPS Journal, 2010, 12, 330-337.	2.2	68
31	Pulmonary Immunization Using Antigen 85-B Polymeric Microparticles to Boost Tuberculosis Immunity. AAPS Journal, 2010, 12, 338-347.	2.2	54
32	Pulmonary Immunization of Guinea Pigs with Diphtheria CRM-197 Antigen as Nanoparticle Aggregate Dry Powders Enhance Local and Systemic Immune Responses. AAPS Journal, 2010, 12, 699-707.	2.2	36
33	Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis. Tuberculosis, 2010, 90, 188-196.	0.8	26
34	Dry Powder PA-824 Aerosols for Treatment of Tuberculosis in Guinea Pigs. Antimicrobial Agents and Chemotherapy, 2010, 54, 1436-1442.	1.4	72
35	Inhaled Drug Delivery for Tuberculosis Therapy. Pharmaceutical Research, 2009, 26, 2401-2416.	1.7	131
36	Screening for Potential Adjuvants Administered by the Pulmonary Route for Tuberculosis Vaccines. AAPS Journal, 2009, 11, 139-147.	2.2	28

Pavan Muttil

#	Article	IF	CITATIONS
37	Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy. Indian Journal of Experimental Biology, 2009, 47, 469-74.	0.5	20
38	A hand-held apparatus for "nose-only―exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. European Journal of Pharmaceutical Sciences, 2008, 34, 56-65.	1.9	60
39	Immunization by a bacterial aerosol. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4656-4660.	3.3	137
40	Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. Journal of Antimicrobial Chemotherapy, 2007, 59, 499-506.	1.3	84
41	Inhalable microparticles containing large payload of anti-tuberculosis drugs. European Journal of Pharmaceutical Sciences, 2007, 32, 140-150.	1.9	160